Literature DB >> 9855008

Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers.

D L Tang1, A Rundle, D Warburton, R M Santella, W Y Tsai, S Chiamprasert, Y Z Hsu, F P Perera.   

Abstract

This molecular epidemiologic case-control study of lung cancer incorporated three complementary biomarkers: the glutathione S-transferase M1 (GSTM1) null genotype, a potential marker of susceptibility, and polycyclic aromatic hydrocarbon-DNA adducts (PAH-DNA) and sister chromatid exchanges (SCE), both indicators of environmentally induced genetic damage. Associations between biomarkers and lung cancer were investigated, as were possible gene-environment interactions between the GSTM1 null genotype and tobacco smoke exposure. Subjects included 136 primary non-small cell lung cancer surgical patients and 115 controls at the Columbia Presbyterian Medical Center. Questionnaire and Tumor Registry data, pre-treatment blood samples and biomarker measurements on blood were obtained. Overall, GSTM1 null genotype was significantly associated with lung cancer [odds ratio (OR) = 2.04, 95% confidence interval (CI) = 1.13-3.68]. ORs for GSTM1 and lung cancer were significant in females (2.50, 1.09-5.72) and smokers (2.25, 1.11-4.54) and not significant in males (1.4, 0.58-3.38) and non-smokers (0.88, 0.18-4.33). However, ORs for males versus females and smokers versus non-smokers did not differ significantly. The OR for GSTM1 and lung cancer in female smokers was 3.03 (1.09-8.40), compared with 1.42 (0.53-4.06) in male smokers. In contrast to PAH-DNA adducts in leukocytes, SCE did not differ between cases and controls. Neither biomarker differed significantly between the two GSTM1 genotypes. The combined effect of elevated PAH-DNA adducts and GSTM1 genotype on case-control status (16.19, 1.2-115) appeared multiplicative. Results suggest that the effect of the GSTM1 null genotype is greatest in female smokers, which is consistent with other evidence that indicates that women are at higher risk of lung cancer than males, given equal smoking. Persons with both the GSTM1 deletion and elevated PAH-DNA adducts may represent a sensitive subpopulation with respect to carcinogens in tobacco smoke and other environmental media.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855008     DOI: 10.1093/carcin/19.11.1949

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  20 in total

1.  Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines.

Authors:  Scott M Langevin; John P A Ioannidis; Paolo Vineis; Emanuela Taioli
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

2.  CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations.

Authors:  Catherine A Wassenaar; Yuanqing Ye; Qiuyin Cai; Melinda C Aldrich; Joanne Knight; Margaret R Spitz; Xifeng Wu; William J Blot; Rachel F Tyndale
Journal:  Carcinogenesis       Date:  2014-11-21       Impact factor: 4.944

Review 3.  Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer.

Authors:  Peter N Lee; Barbara A Forey; Katharine J Coombs
Journal:  BMC Cancer       Date:  2012-09-03       Impact factor: 4.430

Review 4.  Lung cancer in women.

Authors:  Raúl Barrera-Rodriguez; Jorge Morales-Fuentes
Journal:  Lung Cancer (Auckl)       Date:  2012-12-15

Review 5.  Better cancer biomarker discovery through better study design.

Authors:  Andrew Rundle; Habibul Ahsan; Paolo Vineis
Journal:  Eur J Clin Invest       Date:  2012-09-23       Impact factor: 4.686

6.  Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.

Authors:  Snjezana Dogan; Ronglai Shen; Daphne C Ang; Melissa L Johnson; Sandra P D'Angelo; Paul K Paik; Edyta B Brzostowski; Gregory J Riely; Mark G Kris; Maureen F Zakowski; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-09-26       Impact factor: 12.531

7.  Physical activity and lung cancer among non-smokers: a pilot molecular epidemiological study within EPIC.

Authors:  Andrew Rundle; John Richie; Karen Steindorf; Marco Peluso; Kim Overvad; Ole Raaschou-Nielsen; Francoise Clavel-Chapelon; Jacob P Linseisen; Heiner Boeing; Antonia Trichopoulou; Domenico Palli; Vittorio Krogh; Rosario Tumino; Salvatore Panico; Hendrik B Bueno-De-Mesquita; Petra H Peeters; Eiliv Lund; Carlos A Gonzalez; Carmen Martinez; Miren Dorronsoro; Aurelio Barricarte; M Jose Tormo; Josèr Quiros; Antonio Agudo; Goran Berglund; Bengt Jarvholm; Sheila Bingham; Timothy J Key; Emmanuelle Gormally; Rodolfo Saracci; Rudolf Kaaks; Elio Riboli; Paolo Vineis
Journal:  Biomarkers       Date:  2010-02       Impact factor: 2.658

8.  An association between BPDE-like DNA adduct levels and CYP1A1 and GSTM1 polymorphisma in pterygium.

Authors:  Jai-Nien Tung; Heng-Hsiung Wu; Chun-Chi Chiang; Yi-Yu Tsai; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Mol Vis       Date:  2010-04-08       Impact factor: 2.367

Review 9.  Worldwide trend of increasing primary adenocarcinoma of the lung.

Authors:  Haruhiko Nakamura; Hisashi Saji
Journal:  Surg Today       Date:  2013-06-11       Impact factor: 2.549

10.  N-7-Alkyl-2'-Deoxyguanosine as surrogate biomarkers for N-nitrosamine exposure in human lung.

Authors:  Natarajan Ganesan; Shunji Kato; Elise D Bowman; Peter G Shields
Journal:  Int J Canc Prev       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.